|
Impaired cognition
|
0.010 |
Biomarker
|
disease |
BEFREE |
CTRP13 may be a surrogate biomarker of NAFLD symptoms and associated with hepatocellular damage, dyslipidemia, and cognitive dysfunction.
|
30247335 |
2019 |
|
Hyperleukocytosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
A cohort of 357 patients with hyperleukocytosis (159 patients with white blood count [WBC] 50 K-100 K, 198 patients with WBC ≥ 100 K) was compared to 918 patients without hyperleukocytosis.
|
28370339 |
2017 |
|
Neurobehavioral Manifestations
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Association of CTRP13 With Liver Enzymes and Cognitive Symptoms in Nonalcoholic Fatty Liver Disease.
|
30247335 |
2019 |
|
Coronary Arteriosclerosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Association of C1q/TNF-Related Protein-3 (CTRP3) and CTRP13 Serum Levels with Coronary Artery Disease in Subjects with and without Type 2 Diabetes Mellitus.
|
28033351 |
2016 |
|
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Association of C1q/TNF-Related Protein-3 (CTRP3) and CTRP13 Serum Levels with Coronary Artery Disease in Subjects with and without Type 2 Diabetes Mellitus.
|
28033351 |
2016 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
C1q/tumor necrosis factor-related protein 13 (CTRP13) is a secreted adipokine that can ameliorate atherosclerosis and vascular calcification.
|
31676569 |
2020 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
C1q/tumor necrosis factor-related protein 13 (CTRP13) is a secreted adipokine that can ameliorate atherosclerosis and vascular calcification.
|
31676569 |
2020 |
|
Vascular calcification
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
C1q/tumor necrosis factor-related protein 13 (CTRP13) is a secreted adipokine that can ameliorate atherosclerosis and vascular calcification.
|
31676569 |
2020 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Complement 1q like-3 (C1ql3) secreted protein was identified as a hub gene affecting islet function in obesity.
|
31300714 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
Herein, we demonstrate a streamlined approach to effectively screen and determine the function of secreted proteins in islets, and identified C1ql3 as a putative contributor to reduced insulin secretion in obesity, linking C1ql3 to an increased susceptibility to type 2 diabetes.
|
31300714 |
2019 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the role of CTRP13 in regulating endothelial function in diabetes has yet to be explored.
|
31676569 |
2020 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
However, the role of CTRP13 in regulating endothelial function in diabetes has yet to be explored.
|
31676569 |
2020 |
|
Polycystic Ovary Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, we did not observe any significant differences in serum levels of adiponectin, CTRP12, and CTRP13 between the overweight/obese and normal weight subgroups in PCOS and non-PCOS women.
|
30540803 |
2018 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
In summary, these findings define CTRP13 as a novel approach for preventing atherosclerotic plaque formation via modulation of lipid uptake and foam-cell migration.-Wang, C., Xu, W., Liang, M., Huang, D., Huang, K. CTRP13 inhibits atherosclerosis via autophagy-lysosome-dependent degradation of CD36.
|
30222079 |
2019 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
In summary, these findings define CTRP13 as a novel approach for preventing atherosclerotic plaque formation via modulation of lipid uptake and foam-cell migration.-Wang, C., Xu, W., Liang, M., Huang, D., Huang, K. CTRP13 inhibits atherosclerosis via autophagy-lysosome-dependent degradation of CD36.
|
30222079 |
2019 |
|
Vascular calcification
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In summary, these findings reveal that CTRP13 regulation is a novel method for the prevention of vascular calcification, representing a novel mechanism of the regulation of Runx2 expression in VSMCs.-Li, Y., Wang, W., Chao, Y., Zhang, F., Wang, C. CTRP13 attenuates vascular calcification by regulating Runx2.
|
31145871 |
2019 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells.
|
31220743 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells.
|
31220743 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells.
|
31220743 |
2019 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells.
|
31220743 |
2019 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells.
|
31220743 |
2019 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells.
|
31220743 |
2019 |
|
Cholangiocarcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In this study, (±)-kusunokinin and its derivative, (±)-bursehernin, were synthesized and investigated for their anticancer activities on cell viability, cell cycle arrest and apoptosis in cancer cell lines including breast cancer (MCF-7, MDA-MB-468 and MDA-MB-231), colon cancer (HT-29) and cholangiocarcinoma (KKU-K100, KKU-M213 and KKU-M055) cells.
|
31220743 |
2019 |
|
Coronary Arteriosclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, we collected blood samples from patients of coronary artery diseases and apolipoprotein E (ApoE)<sup>-/-</sup> mice that were fed a Western diet for 12 wk to induce atherosclerosis and found that serum CTRP13 level was decreased.
|
30222079 |
2019 |
|
Coronary Artery Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, we collected blood samples from patients of coronary artery diseases and apolipoprotein E (ApoE)<sup>-/-</sup> mice that were fed a Western diet for 12 wk to induce atherosclerosis and found that serum CTRP13 level was decreased.
|
30222079 |
2019 |